Dopamine overdose hypothesis: Evidence and clinical implications

Movement Disorders

Volumn 28, Issue 14, 2013, Pages 1920-1929

  Vaillancourt, David E ^a,b   Schonfeld, Daniel ^a   Kwak, Youngbin ^c   Bohnen, Nicolaas I ^d,e   Seidler, Rachael ^d,e  

^a UNIVERSITY OF FLORIDA   (United States)

^b University of Florida   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Dopamine; Dorsal striatum; Learning; Prefrontal cortex; Ventral striatum

Indexed keywords

BROMOCRIPTINE; CARBIDOPA; CARBOXYLYASE; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE 2 RECEPTOR; LEVODOPA; PLACEBO; SULPIRIDE;

ADAPTIVE BEHAVIOR; BRAIN DEPTH STIMULATION; BRAIN REGION; CHOREA; COGNITION; CORPUS STRIATUM; DAILY LIFE ACTIVITY; DNA POLYMORPHISM; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG OVERDOSE; DYSKINESIA; DYSTONIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPOTHESIS; LEARNING; MESOLIMBIC DOPAMINERGIC SYSTEM; MOTOR DYSFUNCTION; NEUROIMAGING; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RESPONSE TIME; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM; WORKING MEMORY;

DOPAMINE; DORSAL STRIATUM; LEARNING; PREFRONTAL CORTEX; VENTRAL STRIATUM;

BRAIN; COGNITION DISORDERS; DOPAMINE; DOPAMINE AGENTS; HUMANS; LEARNING DISORDERS; LEVODOPA; PARKINSON DISEASE;

EID: 84889684919     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25687     Document Type: Review

References (66)

1. Carlsson A, Lindqvist M, Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200-1200.
2. Watts RL, Koller WC, editors. Movement Disorders: Neurologic Principles and Practice. 2nd ed. New York: McGraw-Hill; 2004.
3. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-1143.
4. Kwak Y, Muller ML, Bohnen NI, Dayalu P, Seidler RD. Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease. J Neurophysiol 2010;103:942-949.
5. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006;30:1-23.
6. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 1988;111(pt 2):299-321.
7. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000;38:596-612.
8. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9:1200-1213.
9. Robert G, Drapier D, Verin M, Millet B, Azulay JP, Blin O. Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology. Mov Disord 2009;24:2316-2327.
10. Wiecki TV, Frank MJ. Neurocomputational models of motor and cognitive deficits in Parkinson's disease. Prog Brain Res 2010;183:275-297.
11. Dahlstroem A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1964;232(suppl):231-255.
12. Bjorklund A, Lindvall O. Dopamine-containing systems in the CNS. In: Bjorklund A, Hokfelt T, editors. Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier; 1984:55-122.
13. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(pt 5):2283-2301.
14. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
15. Du G, Lewis MM, Sen S, et al. Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord 2012;27:1636-1643.
16. Vaillancourt DE, Spraker MB, Prodoehl J, Zhou XJ, Little DM. Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. Neurobiol Aging 2012;33:35-42.
17. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]-dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
18. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119(pt 2):585-591.
19. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009;132(pt 11):2970-2979.
20. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
21. Cools R, Clark L, Owen AM, Robbins TW. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci 2002;22:4563-4567.
22. Sohn MH, Ursu S, Anderson JR, Stenger VA, Carter CS. The role of prefrontal cortex and posterior parietal cortex in task switching. Proc Natl Acad Sci U S A 2000;97:13448-13453.
23. Yin HH, Knowlton BJ, Balleine BW. Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. Eur J Neurosci 2004;19:181-189.
24. Kimchi EY, Torregrossa MM, Taylor JR, Laubach M. Neuronal correlates of instrumental learning in the dorsal striatum. J Neurophysiol 2009;102:475-489.
25. Rolls ET. The orbitofrontal cortex and reward. Cereb Cortex 2000;10:284-294.
26. Heekeren HR, Wartenburger I, Marschner A, Mell T, Villringer A, Reischies FM. Role of ventral striatum in reward-based decision making. Neuroreport 2007;18:951-955.
27. Graef S, Biele G, Krugel LK, et al. Differential influence of levodopa on reward-based learning in Parkinson's disease [serial online]. Front Hum Neurosci 2010;4:169.
28. Knowlton BJ, Squire LR, Gluck MA. Probabilistic classification learning in amnesia. Learn Mem 1994;1:106-120.
29. Shohamy D, Myers CE, Kalanithi J, Gluck MA. Basal ganglia and dopamine contributions to probabilistic category learning. Neurosci Biobehav Rev 2008;32:219-236.
30. Knowlton BJ, Mangels JA, Squire LR. A neostriatal habit learning system in humans. Science 1996;273:1399-1402.
31. Shohamy D, Myers CE, Geghman KD, Sage J, Gluck MA. L-dopa impairs learning, but spares generalization, in Parkinson's disease. Neuropsychologia 2006;44:774-784.
32. Poldrack RA, Prabhakaran V, Seger CA, Gabrieli JD. Striatal activation during acquisition of a cognitive skill. Neuropsychology 1999;13:564-574.
33. Sawaguchi T, Matsumura M, Kubota K. Catecholaminergic effects on neuronal activity related to a delayed response task in monkey prefrontal cortex. J Neurophysiol 1990;63:1385-1400.
34. Wang Y, Goldman-Rakic PS. D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons. Proc Natl Acad Sci U S A 2004;101:5093-5098.
35. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995;376:572-575.
36. Seamans JK, Durstewitz D, Christie BR, Stevens CF, Sejnowski TJ. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci U S A 2001;98:301-306.
37. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001;21:3628-3638.
38. Frank MJ, Loughry B, O'Reilly RC. Interactions between frontal cortex and basal ganglia in working memory: a computational model. Cogn Affect Behav Neurosci 2001;1:137-160.
39. Cools R, Frank MJ, Gibbs SE, Miyakawa A, Jagust W, D'Esposito M. Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. J Neurosci 2009;29:1538-1543.
40. van der Schaaf ME, van Schouwenburg MR, Geurts DE, Schellekens AF, Buitelaar JK, Verkes RJ, Cools R. Establishing the dopamine dependency of human striatal signals during reward and punishment reversal learning [published online ahead of print 25 November 2012]. Cereb Cortex 2012.
41. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
42. Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [(18)F]dopa-PET study. Brain 1999;122(pt 9):1637-1650.
43. Kwak Y, Bohnen NI, Muller ML, Dayalu P, Burke DT, Seidler RD. Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease. Behav Brain Res 2013;245:128-136.
44. Kwak Y, Muller ML, Bohnen NI, Dayalu P, Seidler RD. L-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease. Behav Brain Res 2012;230:116-124.
45. Seidler RD, Purushotham A, Kim SG, Ugurbil K, Willingham D, Ashe J. Neural correlates of encoding and expression in implicit sequence learning. Exp Brain Res 2005;165:114-124.
46. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning. Curr Opin Neurobiol 2002;12:217-222.
47. Lehericy S, Benali H, Van de Moortele PF, et al. Distinct basal ganglia territories are engaged in early and advanced motor sequence learning. Proc Natl Acad Sci U S A 2005;102:12566-12571.
48. Carbon M, Eidelberg D. Functional imaging of sequence learning in Parkinson's disease. J Neurol Sci 2006;248(1-2):72-77.
49. Feigin A, Ghilardi MF, Carbon M, et al. Effects of levodopa on motor sequence learning in Parkinson's disease. Neurology 2003;60:1744-1749.
50. Carbon M, Ghilardi MF, Feigin A, et al. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp 2003;19:197-211.
51. Ghilardi MF, Feigin AS, Battaglia F, et al. L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease. Parkinsonism Relat Disord 2007;13:146-151.
52. Argyelan M, Carbon M, Ghilardi MF, et al. Dopaminergic suppression of brain deactivation responses during sequence learning. J Neurosci 2008;28:10687-10695.
53. Kwak Y, Bohnen NI, Muller ML, Dayalu P, Seidler RD. Striatal denervation pattern predicts levodopa effects on sequence learning in Parkinson's disease. J Mot Behav 2013;45:423-429.
54. Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004;19:885-891.
55. Williams-Gray CH, Hampshire A, Barker RA, Owen AM. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain 2008;131(pt 2):397-408.
56. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007;27:4832-4838.
57. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994;63:972-979.
58. Mazei MS, Pluto CP, Kirkbride B, Pehek EA. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res 2002;936(1-2):58-67.
59. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652-654.
60. MacDonald AA, Monchi O, Seergobin KN, Ganjavi H, Tamjeedi R, MacDonald PA. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function. Mov Disord 2013;28:153-160.
61. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012;366:511-519.
62. Corcos DM, Robichaud JA, David FJ, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord 2013;28:1230-1240.
63. Ray NJ, Strafella AP. Imaging impulse control disorders in Parkinson's disease and their relationship to addiction. J Neural Transm 2013;120:659-664.
64. Cools R, Altamirano L, D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006;44:1663-1673.
65. Funkiewiez A, Ardouin C, Cools R, et al. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease. Mov Disord 2006;21:1656-1662.
66. Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007;32:180-189.